ALKERMES | ALKS - Selling And Administration Expenses

Stock Price
32.26
Daily Change
0.35 1.10%
Monthly
-2.57%
Yearly
-9.18%
Q1 Forecast
30.94

ALKERMES reported $171.77M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
ALKERMES USD 171.77M 17.9M Sep/2025
Amgen USD 1.94B 237M Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Coherus Biosciences USD 26.02M 8.57M Mar/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Heron Therapeutics USD 23.34M 4.18M Sep/2024
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
J&J USD 6.75B 831M Dec/2025
Malin Corporation EUR 1.1M 400K Dec/2024
Merck USD 2.85B 215M Dec/2025
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Otsuka Holdings JPY 278.3B 24.08B Dec/2025
Ovoca Bio EUR 2.96M 8K Jun/2022
Pfizer USD 4.08B 894M Dec/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025